Just and Equitable Enrollment to Pivotal Clinical Trials in Hematologic Malignancies

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Namrata S. Chandhok

Honoraria: Healio, Clinical Care Options

Consulting or Advisory Role: Servier

Mikkael A. Sekeres

Consulting or Advisory Role: Celgene, Millennium, Pfizer, Novartis, Syros Pharmaceuticals, Kurome Therapeutics

Research Funding: Takeda (Inst), Pfizer (Inst), Bristol Myers Squibb (Inst)

No other potential conflicts of interest were reported.